"MAD 4 IP" - MAD FOR IP, MADE FOR IP
Hi IP MADs,
The imminent arrival of the dreaded
"patent cliff" has been haunting the pharmaceutical industry for
years. With the patents of an
unprecedented number of blockbuster brand drugs expiring in 2012, it
will be a bitter year for patent owners.
Table: Top 10 Drugs Going To Be
Off-Patent In 2012
Sr. No.
|
Patent expiring in 2012
|
Active Pharmaceutical Ingredient
|
Company
|
Use
|
2010 U.S. Sales
|
1
|
Plavix
|
Clopidrogrel
|
Bristol-myers squibb /
sanofi-aventis |
Anti-platelet
|
$6,154,000,000
|
2
|
Seroquel
|
Quetiapine
|
Astrazeneca
|
Antipsychotic
|
$3,747,000,000
|
3
|
Singulair
|
Montelukast
|
Merck
|
Asthma
|
$3,224,000,000
|
4
|
Actos
|
Pioglitazone
|
Takeda
|
Type 2 diabetes
|
$3,351,000,000
|
5
|
Enbrel
|
Etanercept
|
Amgen
|
Arthritis
|
$3,304,000,000
|
6
|
Lexapro
|
Escitalopram
|
Forest
|
Antidepressant
|
$2,560,000,000
|
7
|
Diovan/HCT
|
Valsartan/ Hydrychlorothiazide
|
Novartis
|
Angiotensin II receptor
Antagonist/ Thiazide Diuretic
|
$2,533,000,000
|
8
|
Tricor
|
Fenofibrate
|
Abbott
|
Hypercholesterolemia and
Hypertriglyceridemia.
|
$1,345,000,000
|
9
|
Geodon
|
Ziprasidone
|
Pfizer
|
Atypical Antipsychotic
|
$1,281,000,000
|
10
|
Provigil
|
Modafinil
|
Cephalon
|
Analeptic
|
$1,133,000,000
|
References
1.
http://www.dailyfinance.com/2011/02/27/top-selling-drugs-are-about-to-lose-patent-protection-ready/
3.
http://info.articleonepartners.com/blog/bid/74762/Top-5-U-S-Drug-Patent-Expirations-in-2012-Part-I
4.
http://info.articleonepartners.com/blog/bid/75063/Top-5-U-S-Drug-Patent-Expirations-in-2012-Part-II
For more information please follow "Mad 4 IP"
For more information please follow "Mad 4 IP"
Categories:
Patent,
Patent Expiration
